Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. Multiple genomic alterations occur in PTC, and gene rearrangements are one of them. Here we screened 14 tumors for novel fusion transcripts by RNA-Seq. Two samples harboring RET/PTC1 and RET/PTC3 rearrangements were positive controls whereas the remaining ones were negative regarding the common PTC alterations. We used Sanger sequencing to validate potential fusions. We detected 2 novel potentially oncogenic transcript fusions: TG-FGFR1 and TRIM33-NTRK1. We detected 4 novel fusion transcripts of unknown significance accompanying the TRIM33-NTRK1 fusion:
| INTRODUCTION
Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. The most common driver alterations in PTC are point mutations in BRAF and RAS genes (KRAS, HRAS, and NRAS) and rearrangements of the RET gene (RET/PTC rearrangements). According to The Cancer Genome Atlas (TCGA) study, these alterations occur in 59.7%, 13%, and 6.3% of the PTC cases, respectively, and the total prevalence of gene rearrangements is 15%. 1 Multiple gene rearrangements occur in PTC, and RET/PTC are the most prevalent ones. 1 RET/PTC rearrangements are associated with younger age and radiation exposure. 2 As documented in the previous studies, detection of these alterations in cytological specimens may be helpful in improving the accuracy of the diagnosis of PTC. 3 Multiple gene rearrangements can be screened using the molecular test ThyroSeq; these rearrangements entail a high risk of cancer. 4 However, it is worth noting that gene rearrangements can also be found in some benign thyroid diseases. 5 In recent years, our knowledge about genomic rearrangements and transcript fusions in PTC has widely expanded, mostly thanks to # These authors contributed equally to this work.
RNA-Seq, what led to the detection of numerous novel gene rearrangements in PTC. 1, [6] [7] [8] [9] [10] [11] The most important was the detection of ETV6-NTRK3, which occurs in 2%-14.5% of PTC patients. 8 In PTCs, the most common 5 0 partner in gene rearrangements are RET, BRAF, NTRK3, THADA, PPARG, NTRK1, and ALK. 1 All of them, except THADA, code for proteins with tyrosine kinase domains.
Our study aimed to detect novel transcript fusions in PTC to expand the knowledge about genetic alterations in this malignancy.
| MATERIALS AND METHODS

| Samples
Fresh-frozen material from 14 PTCs was used in this study. Surgical were evaluated due to sample availability limitations (details in Supporting Information Table S1 ).
There were 3 males and 11 females in our study group diagnosed with classical (10 cases) and follicular (4 cases) PTC variants. Young patients were preferred during sample selection: the mean age at diagnosis was 24 years, with a median of 26 years (range:
13-40 years). The mean and median tumor diameters were 17 mm and 15 mm, respectively (range 10-34 mm). Four PTCs were multifocal, 5 with capsule invasion, and 1 with vascular invasion. Lateral neck lymph node metastases were present in 7 patients. Neither local recurrence nor distant metastases were present in any patient from the study group. The histopathological characteristics of the tumors are given in Table 1 .
| RNA-Seq
To detect novel fusion transcripts in PTC, we performed paired-end RNA-Seq on 12 PTC samples that were negative regarding most common PTC genetic alterations (BRAF V600E mutation, mutations in codons 12, 13, and 61 of HRAS, NRAS, and KRAS genes, PAX8-PPARG, RET/PTC1, and RET/PTC3). We also performed paired-end RNA-Seq experiment on 1 case with RET/PTC1 and 1 case with RET/PTC3 as positive controls.
Total RNA was extracted from homogenized frozen tissue using
Mini Kits (Qiagen GmbH, Hilden, Germany). RNA quantity was measured by NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE)
minispectrophotometer whereas its quality was estimated by Agilent 2100 using RNA 6000 Nano Assay (Agilent Technologies, Santa Clara, CA). Only high-quality RNA (RNA Integrity Number > 6.5) was used. 
| RNA-Seq data analysis
Read's quality was assessed using FastQC version 0.9.3. 12 Raw FASTQ data were trimmed and filtered using Prinseq-lite version 0.20.4, and only high-quality reads were used in the further analysis.
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Fusion transcripts detection was performed using three bioinformatics tools in order to achieve a high sensitivity: TopHat-Fusion (TopHat version 2.0.10), 14 ChimeraScan version 0.4.5, 15 and SnowShoes-FTD version 2.0 Build 37. 16 Fusion transcripts detected with these tools were further filtered with in-house tools in order to filter out false positive findings (details provided in supplementary methods). Genome version GRCh37/hg19 was used in all these analyses.
The list of fusion transcripts present in normal samples was obtained from the paper published by Babiceanu et al. 3 | RESULTS
| Detection of fusion transcripts by RNA-Seq
In order to detect novel fusion transcripts in PTC, we performed paired-end RNA-Seq experiment on 14 PTC tumor samples. After filtering and trimming of raw reads, we obtained an average of 13.5 million read pairs in each sample. The read length was 120 bp in 6 samples and 50 bp in 8 samples (Supporting Information Table S3 ).
We detected 28 fusion events by TopHat-Fusion, 96 by ChimeraScan, and 34 by SnowShoes-FTD (Supporting Information Tables S4-S6 ).
In total, we detected 126 fusion events. Seventy-three of them were read-throughs or were detected in normal samples as depicted by Babiceanu et al 17 and these were beyond our interest (Supporting Information Table S7 ). The remaining 53 fusion transcripts, which were not read-throughs and not detected in normal samples, were further manually inspected (Supporting Information Table S8 ).
We manually selected candidate fusion transcripts potentially tumorigenic, which involved genes with known cancer-associated functions. We also selected all candidate fusion transcripts that were detected by more than one program. Final list consisted of 18 transcript fusions (Table 2) , found in 11 of 14 tumor samples.
The following novel transcript fusions were detected with RNASeq method: TG-FGFR1, FGFR1-TG, two isoforms of TRIM33-NTRK1, ARID1B-PSMA1, TAF4B-WDR1, ABI2-MTA3, ZSWIM5-TP53BP2, and the novel isoform of CCDC6-RET. RET/PTC1 and RET/PTC3 fusion transcripts were found, as expected, in positive control samples. We also detected known oncogenic fusion transcripts: TFG-NTRK1, ETV6-NTRK3 (in three samples), MKRN1-BRAF, and EML4-ALK.
| Validation of fusion transcripts
We performed validation by direct Sanger sequencing for all 9 novel fusion transcripts. We confirmed the existence of 8/9 fusions: TG-FGFR1, FGFR1-TG, one isoform of TRIM33-NTRK1 (with a breakpoint in chr1:114952806-chr1:156845312), ARID1B-PSMA1, TAF4B-WDR1, ABI2-MTA3, ZSWIM5-TP53BP2 as well as the novel isoform of CCDC6-RET (Figures 1 and 2 ; Supporting Information Figures S1-S6). We did not confirm the second TRIM33-NTRK1 fusion isoform, with a breakpoint in chr1:114952806-chr1:156846192. When we used primers designed for that TRIM33-NTRK1 isoform, we did not observe the expected sequence.
| Novel fusion transcripts
We detected 2 novel in-frame fusion transcripts, which are potential driver alterations: TG-FGFR1 and TRIM33-NTRK1.
We identified a novel fusion of thyroglobulin (TG) and fibroblast by TG and the whole protein kinase domain encoded by FGFR1 are retained in this fusion. In NIS164 sample harboring TG-FGFR1, also a reciprocal fusion FGFR1-TG was detected, which fuses exons 1-8 of FGFR1 to exon 48 of TG (Supporting Information Figure S1 ).
We identified a novel fusion of tripartite motif containing In the sample PTC131, apart from the novel TRIM33-NTRK1
fusion, we detected 4 other novel fusion transcripts of unknown significance: ZSWIM5-TP53BP2, TAF4B-WDR1, ABI2-MTA3, and ARID1B-PSMA1 (Supporting Information Figures S2-S5 ). All 4 fusions apart from ABI2-MTA3 are in-frame. ABI2-MTA3 is out-of-frame and a premature stop codon occurs in 10th codon after the breakpoint.
We also found a novel in-frame isoform of the known oncogenic fusion CCDC6-RET in PTC106 sample (Supporting Information Figure S6 ).
In the novel isoform, exons 1-8 of CCDC6 (ENST00000263102) are fused to exons 12-20 of RET (ENST00000355710), in contrary to the most common CCDC6-RET rearrangement encompassing over 98% of cases, in which exon 1 of CCDC6 is fused to exons 12-20 of the RET gene (Supporting Information Figure S6 ). 18 The whole protein kinase domain encoded by RET is retained in the novel fusion isoform.
| Known fusion transcripts
Using RNA-Seq, NCOA4-RET (RET/PTC1) and CCDC6-RET (RET/PTC3) were found, as expected, in positive control samples. In the remaining samples, we also detected in-frame fusion transcripts already reported in the literature: two isoforms of TFG-NTRK1, ETV6-NTRK3 (in 3 samples), Figures S7-S11 ).
MKRN1-BRAF, and EML4-ALK (Supporting Information
In all of them, 3 0 partner encodes tyrosine kinase domain, and the whole domain is retained in the predicted fusion protein.
In both the TFG-NTRK1 isoforms that we detected, a fusion between exon 6 of TFG (ENST00000418917 or ENST00000240851) and exon 10 of NTRK1 (ENST00000524377) was present. The two isoforms differed in the length of exon 6 of the TFG gene, which is 129 bp in TFG variant ENST00000418917 and 141 bp in TFG variant ENST00000240851 (Supporting Information Figures S7, S8 ). In ETV6-NTRK3, the fusion between exon 4 of ETV6 (ENST00000396373) and exon 14 of NTRK3 (ENST00000394480) was present (Supporting Information Figure S9 ). We detected ETV6-NTRK3 in 3 samples, and it was the most prevalent alteration in our group. Two of three samples harboring ETV6-NTRK3 were follicular variant of PTC. In MKRN1-BRAF, the fusion between exon 4 of MKRN1 (ENST00000255977) and exon 11 of BRAF (ENST00000288602) was present (Supporting Information Figure S10 ).
In EML4-ALK, the fusion between exon 13 of EML4 (ENST00000318522) ABI2 is a KMT2A translocation partner in acute myeloid leukemia. 43 The fusion transcript, detected by us, retained the SH3 domain; however, it does not have ankyrin (Ank) repeats. Lack of these domains may inhibit TP53BP2 tumor suppressor functions.
The last fusion, accompanying the TRIM33-NTRK1 rearrangement, is the ARID1B-PSMA1 fusion. ARID1B (AT-rich interaction domain 1B) encodes a protein that is a component of the SWI/SNF chromatin remodeling complex, which may play a role in cell-cycle activation.
Tumor suppressor activity of ARID1B has been demonstrated in vitro in pancreatic cancer cells. 44 Moreover, deletions and mutations of this gene have been reported in hepatocellular carcinoma, childhood neuroblastoma, PTC, and other types of cancer. 45 ARID1B has also been identified as an additional ZNF384 fusion partner in pediatric acute lymphoblastic leukemia. 46 PSMA1 (proteasome subunit alpha 1), in turn, was shown to be up-regulated in a number of cancers. 47 We also detected novel in-frame isoform of the known oncogenic fusion CCDC6-RET, which similarly to other RET rearrangements, also retained the RET tyrosine kinase domain leading to RET activation.
In our group of samples, we also found 4 oncogenic fusions already reported in the literature: TFG-NTRK1, ETV6-NTRK3, MKRN1-BRAF, and EML4-ALK. TFG-NTRK1 was previously reported in only a few PTC cases. 27, 48, 49 However, it was not reported in other cancers. 18, 50 The longer of two isoforms detected in our study, TFG (exon 6 of ENST00000240851)-NTRK1 (exon 10 of ENST00000524377), has been already reported in PTC. 1,51 ETV6-NTRK3 was the most prevalent alteration in PTC set analyzed by us, as it was found in 3 samples.
According to the literature, the ETV6-NTRK3 occurs in 2%-14.5% of PTC patients. 8 It also occurs in cancers of the salivary gland, kidney, and other tissues. 18, 50 Two of the three samples harboring ETV6-NTRK3
were follicular variants of PTCs. This is in agreement with recent findings that most post-Chernobyl PTCs in which ETV6-NTRK3 was identified were classified as follicular variant of PTC. 6, 8 The isoform detected in our study, which juxtaposes exon 4 of ETV6 (ENST00000396373) and exon 14 of NTRK3 (ENST00000394480), has been reported in PTC 1, 6, 8, 51 and gastrointestinal stromal tumor. 52 MKRN1-BRAF has been reported in a few cases of PTC. 1, 7 It was also described to be present in anaplastic thyroid cancer, pilocytic astrocytoma, head and neck neuroendocrine carcinoma, colon adenocarcinoma, and low-grade serous ovarian cancer. [53] [54] [55] [56] The isoform detected in our study, which juxtaposes exon 4 of MKRN1 (ENST00000255977) to exon 11 of BRAF (ENST00000288602), has been reported in pilocytic astrocytoma, 54 colon adenocarcinoma 55 and in low-grade serous ovarian cancer.
56
EML4-ALK was reported in PTC in a number of studies. 1, 9, 57, 58 It also occurs in about 7% cases of non-small-cell lung cancer and in other cancers. 50, 59 The isoform detected in our study, which juxtaposes exon 13 of EML4 (ENST00000318522) and exon 20 of ALK (ENST00000389048) was reported in lung carcinoma 59 and papillary thyroid carcinoma. 9, 57 Although the number of analyzed PTC cases is small, they were carefully selected, and only young PTC patients without known somatic mutations of the BRAF and RAS genes, PAX8-PPARG, RET/PTC1, and RET/PTC3 rearrangements were taken into consideration. We found new fusion transcripts with a potential oncogenic role and a number of known rearrangements. Our study shows that although large analyses like TCGA study gave us a lot of new data about PTC biology, still some information is missing, and further analyses are needed. There is no doubt that better understanding of molecular PTC background will open new diagnostic and therapeutic possibilities.
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